Phase 2 data on filgotinib show a reduction in risk of flare in patients with uveitis and good tolerance in one of the first studies of a JAK inhibitor in uveitis.
Investegate announcements from Galapagos NV, Galapagos to showcase commitment to rheumatoid arthritis care at the upcoming European League Against Rheumatism congress
Celebrating EULAR's 75th anniversary with focus on a new era of rheumatoid arthritis care Mechelen, Belgium; 25 May 2022, 22.01 CET; Galapagos NV (Euronext & Nasdaq: GLPG) will